SRPT vs VRTX · rev $1.90B vs P/E 30, rev $12.00B
Sarepta Therapeutics Inc (SRPT) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
SRPT currently screens at market cap $2.34B. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the SRPT and VRTX stock pages for the full models.
Not investment advice.